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Abstract
As part of our continuing investigation of azo-flavonoid derivatives as potential anticancer drug
candidates, a series of 2-aryl-6,7-methylenedioxyquinolin-4-one analogs was designed and
synthesized. The design combined structural features of 2-(2-fluorophenyl)-6,7-
methylenedioxyquinolin-4-one (CHM-1), a previously discovered compound with potent in vivo
antitumor activity, and 2-arylquinolin-4-ones identified by CoMFA models. The newly synthesized
analogs were evaluated for cytotoxicity against seven human cancer cell lines, and structure-activity
relationship (SAR) correlations were established. Analogs 1, 37, and 39 showed potent cytotoxicity
against different cancer cell lines. Compound 1 demonstrated selective cytotoxicity against Hep 3B
(hepatoma) cells. Compound 37 was cytotoxic against HL-60 (leukemia), HCT-116 (colon cancer),
Hep 3B (hepatoma), and SK-MEL-5 (melanoma) cells. Compound 39 exhibited broad cytotoxicity
against all seven cancer cell lines, with IC50 values between 0.07–0.19 µM. Results from mechanism
of action studies revealed that these new quinolone derivatives function as antitubulin agents.
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Introduction
Microtubules of eukaryotic cells are known to play an important role in mitosis.1 Therefore,
compounds that target microtubules have long been investigated as anticancer drugs. Typically,
such compounds arrest cells, at least transiently, in the mitotic phase of the cell cycle. Currently,
two groups of antimitotic agents are used clinically for cancer treatment. Vinca alkaloids and
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estramustine inhibit tubulin polymerization into microtubules, while taxoids and epothilones
stabilize microtubules and consequently interfere with their normal dynamic instability.2, 3
Colchicine is another well-known antimitotic agent used for treating gout and inflammatory
diseases. However, due to its high toxicity, colchicine is not used in cancer therapy.
Combretastatin A-4, with a modified colchicine-like structure, exhibits a lower toxicity profile,
while it still targets the same binding site as colchicine.4, 5 The phosphate prodrug of
combretastatin A-4 (CA-4) is currently in phase III clinical trials as an anticancer agent.6, 7
Although several antimitotic agents are available, due to the structural complexity of vinca
alkaloids and taxoids, there is still a need to identify novel anticancer drugs that target
microtubules but have simplified structures, because such compounds can be readily prepared
in a more cost-effective way.
In recent years, we have designed and synthesized three series of azo-flavonoids as new classes
of antimitotic agents: 2-arylquinolone-4-ones,8–15 2-arylnaphthyridin-4-ones,16–18 and 2-
arylquinazolin-4-ones 19, 20 (Figure 1). Some of these compounds, especially analogs
belonging to the 2-arylnaphthyridin-4-one family, demonstrated significant antitumor and anti-
tubulin activities. In general, a good correlation was found between the cytotoxicity of these
analogs and their inhibitory effects on tubulin polymerization. Additional mechanism of action
studies revealed that the most active of these compounds are also potent inhibitors of colchicine
binding to tubulin. Further modification of the 2-phenylquinolin-4-one series was directed by
computer modeling studies combined with SAR results from previously synthesized
compounds. In the current study, we report the design and syntheses of novel 2-
arylquinolone-4-one analogs, which showed potent and selective inhibitory activities towards
different human cancer cell lines.
Design
Both Conventional Comparative Molecular Field Analysis (CoMFA) and g2 GRS CoMFA
were used to identify structural requirements that may be essential for increasing the binding
affinity of 2-phenylquinolin-4-one and 2-phenylnaphthyridin-4-one analogs for the colchicine
site of tubulin. The training set of the models contained 51 compounds, and the cross-validated
R2 (q2) values for conventional CoMFA and g2 GRS CoMFA were 0.637 and 0.692,
respectively. These QSAR models predicted that a larger heterocyclic aromatic ring at the C-2
position should enhance activity. The predictive power of the models was validated by the
prediction for a test set of 53 compounds with known anti-tubulin potencies, and the predictive
R2 values were 0.546 and 0.426, respectively. Based on this study, new analogs were designed
in both compound series (Figure 2).21 As a proof of concept, the newly designed
arylnaphthyridine analog 2-(3-benzo[b]thienyl)naphthyridin-4-one (A), which has a
benzothienyl ring at the C-2 position of the naphthyridine, exhibited potent cytotoxicity in the
low micromolar to nanomolar concentration range. Further, a mechanism of action study
revealed that the compound also inhibited tubulin polymerization with an IC50 value of 0.37
µM. These results verified the success of our modeling design.18 Thus, the same modifications
were carried out at the C-2 position of the 2-arylquinolin-4-one series in the present study.
In addition, when we re-analyzed results from our prior in vivo antitumor study of selected 2-
phenylquinolin-4-one compounds, we found that analogs with a methylenedioxy functional
group at the C-6 and -7 positions showed superior antitumor and safety profiles compared with
C-6 mono-modified compounds. For instance, 2-(3-methoxyphenyl)-6-pyrrolinylquinolin-4-
one (B, Figure 3) exhibited only moderate antitumor activity at the maximum tolerated dose
(MTD, 25 mg/kg, ip, once weekly for 3 courses) against the OVCAR-3 xenograft model in
nude mice. In contrast, 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one (CHM-1,
Figure 3) extended the life span of tumor-bearing mice by 124%, 133% and 79%, at dosages
of 200, 134 and 79 mg/kg (ip, once weekly for 3 courses), respectively. Additionally, the
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maximum tolerated dose of CHM-1 was not reached at the highest tested dosage of 200 mg/
kg.22 Currently, the phosphate prodrug of CHM-1 (CHM-1-P-Na, Figure 4) is under
preclinical study.22, 23 Therefore, the methylenedioxy ring of CHM-1 was also incorporated
into our newly designed 2-arylquinolone-4-one series, which led to the syntheses of 2-aryl-6,7-
methylenedioxyquinolin-4-one analogs (1, 36–45). Compound 56, a ring isomer of analog
39, was also synthesized, because ring isomerization is a common approach in structure-
activity relationship studies of a compound series.
Chemistry
The synthetic procedure for target compounds (1, 36–45) is illustrated in Scheme 1. The starting
arylcarboxylic acids (3–13) were first treated with oxalyl chloride to form the corresponding
acid chlorides (14–24), which were then reacted with 2-amino-4,5-
methylenedioxyacetophenone (2) to give the corresponding amides (25–35). The intermediates
(25, 27–34) were subjected to a cyclization reaction in t-BuOH, in the presence of t-BuOK, to
afford the corresponding 2-arylquinolin-4-one analogs (1, 37–44). Cyclization was also carried
out with 1,4-dioxane as solvent, in the presence of NaOH, which yielded the target products
(1, 36, 39 and 45) in yields of 40%–74%. When the starting compounds (25–26, 28–32 and
34) were treated with t-BuOK in toluene at 90 °C for 72 h, the corresponding deacetylated
products 46–53 were obtained unexpectedly.
Scheme 2 depicts the synthesis of compound 56. The starting material 2 was first treated with
1-naphthylmethyl chloride (54) to give the corresponding amide (55). Compound 55 was then
subjected to a cyclization reaction in 1,4-dioxane, in the presence of NaOH, which yielded 4-
methyl-6,7-methylenedioxy-3-(1-naphthyl)quinolin-2-one (56) as the final product.
Results and Discussion
The newly synthesized 2-aryl-6,7-methylenedioxyquinolin-4-ones (1, 36–45) and the ring
isomer 56 were assayed for in vitro cytotoxicity against seven human cancer cell lines,
including HL-60 (leukemia), HCT-116 (colon cancer), A549 (non-small cell lung carcinoma),
Hep 3B (hepatoma), KB (epidermoid carcinoma of the nasopharynx), KB-VIN (p-
glycoprotein- expressing epidermoid carcinoma of the nasopharynx), and DU145 (prostate
cancer). The cytotoxicity results are summarized in Table 1. Compounds 46–53 were tested
against the HL-60, HCT-116, H226, A549, Hep G2 and A498 cancer cell lines; however, none
of the compounds showed significant activity (IC50 values were >10 µM).
Compound 1 exhibited significant cytotoxicity against Hep 3B cells, with an IC50 value of 0.06
µM, and moderate activity against HL-60 and HCT-116 cells, with IC50 values of 0.17 and
0.14 µM, respectively. This result, along with the prior cytotoxicity data obtained with
compound A, confirmed the prediction generated by conventional and g2 GRS CoMFA that a
larger heterocyclic aromatic ring should be preferred at the C-2 position. In comparison,
replacement of the 3-benzo[b]thienyl group (1) with a 2-benzo[b]thienyl group (36) resulted
in significantly reduced cytotoxicity, demonstrating the importance of the exact linkage of the
aromatic ring moiety.
Bioisosteric replacement of 3-benzo[b]thienyl (1) with 3-benzo[b]furanyl (37) led to increased
potency against two cancer cell lines. Specifically, compared with 1, the cytotoxic activity of
37 increased five-fold against HL-60 (IC50 0.03 µM) and three-fold against HCT-116 (IC50
0.05 µM) cells. The two compounds had similar potency against Hep 3B cells. Most
importantly, 37 retained potency (IC50: 0.59 µM) against KB-VIN cells, a vincristine-resistant
epidermoid carcinoma of the nasopharynx cell line, compared with KB cells (IC50 1.05 µM).
As with 1 and 36, moving the attachment of the benzofuran moiety from 3′ in 37 to 2′ in 38
was detrimental to cytotoxic activity.
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Compound 39, with a 1-naphthyl group rather than a 3-benzo[b]thienyl group (1) at the C-2
position, exhibited potent cytotoxicity towards all seven cancer cell lines, with IC50 values
ranging from 0.07 to 0.19 µM. It should be noted that although 39 showed similar activity
towards the HL-60, HCT-116, and Hep 3B cancer cell lines as compared with 1 and 37, it
showed significantly increased cytotoxicity towards A549, KB, KB-VIN and DU145 cells.
Compound 40, the ring positional isomer of 39, was much less cytotoxic, as was the case with
compounds 36 and 38.
Surprisingly, cytotoxicity was reduced significantly when the C-2 aryl moiety was a quinoline
group, no matter how it was attached (41–44). In addition, expanding the naphthalene ring of
39 to an anthracene (45) lowered the cytotoxicity remarkably. Thus, we speculate that the size
of the C-2 substituted aromatic ring plays an important role in antitumor activity and that the
binding pocket for this portion of the drug molecule is quite small.
Compound 56 was designed as a ring isomer of 39. The in vitro bioassay data showed that
moving the aromatic ring to C-3 and the carbonyl to C-2 to give a cyclic amide completely
abolished cytotoxicity of the compound. Non-cyclic amide analogs 46–53 also exhibited poor
in vitro activity.
In addition to the in vitro cytotoxicity study, we also performed initial mechanism of action
studies with the newly synthesized 2-aryl-6,7-methylenedioxyquinolin-4-one analogs (1, 37–
45). As noted above, 2-arylquinolin-4-ones are azo-flavonoids, which were shown to inhibit
tubulin assembly and the binding of colchicine to tubulin. Therefore, compounds 1 and 37–
45 were tested for their in vitro activities in these assays in comparison with combretastatin
A-4 (CA-4). The results are summarized in Table 2. The data showed that 1, 37, and 39, the
three compounds with the greatest in vitro cytotoxicity, were potent inhibitors of tubulin
assembly, with IC50 values of 0.76, 0.58, and 0.64 µM, respectively. Although all three
compounds were better assembly inhibitors than CA-4 (IC50 1.2 µM), they were less effective
than CA-4 in inhibiting colchicine binding to tubulin.
Furthermore, results from a pharmacokinetic study in a mice model revealed that the 6,7-
methylenedioxy moiety of CHM-1-P-Na is metabolized to an ortho-quinone (D, Figure 4,
unpublished data). It is known that the para-quinone moiety in mitomycin C can be subjected
to one-electron reduction by NADPH-cytochrome C (P450) reductase to form the
corresponding semiquinone radical anion.24 We postulate that similar reduction of the ortho-
quinone moiety of D may take place to form the radical anion product E, which may be further
metabolized or broken down into more cytotoxic metabolites in hypoxic cells. Because severe
hypoxia is a common property of locally advanced solid tumors, this postulate may explain
our finding that 6,7-methylenedioxyquinoline analogs (e.g. CHM-1) showed enhanced in vivo
activity profiles compared with 6-monosubstituted analogs.
Among the active analogs, 37, which showed potent cytotoxicity and reasonable solubility,
was chosen for submission to the National Cancer Institute (NCI, USA) for further screening
against 60 human tumor cell lines. In preliminary screening, 37 showed potent selective
cytotoxicity against many leukemia cell lines (Figure 5). In addition, it also significantly
inhibited the growth of several colon cancer (HCC-2998 and KM-12), CNS cancer (SF-539
and SNB-75), melanoma (SK-MEL-5), and ovarian cancer (IGROV1 and OVCAR-3) cell
lines. Based upon these results, 37 appears to be an attractive candidate for further development
as a potential anticancer agent in the clinic.
In conclusion, a series of 2-aryl-6,7-methylenedioxyquinolin-4-one analogs (1, 36–45) were
designed, synthesized, and evaluated for in vitro cytotoxicity. This design combined two
structural features: larger heterocyclic aromatic rings at the C-2 position as predicted to be
favorable by CoMFA models and a 6,7-methylenedioxy moiety rather than C-6 mono-
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substituted analog based on the improved cytotoxicity of CHM-1 and the metabolic pathway
of CHM-1-P-Na. In our studies, 1 showed selective cytotoxicity against Hep 3B cells, 37 was
active against HL-60, HCT-116, Hep 3B and KB-VIN cells, and 39 had potent cytotoxicity
against all seven cancer cell lines with IC50 values between 0.07–0.19 µM. A mechanism of
action study demonstrated that 1, 37, and 39 also function as antitubulin agents. Compound
37 was further selected for evaluation against 60 human cancer cell lines and was active against
several types of cancer cells. The significant in vitro cytotoxicity of 37 and 39 suggested that
they can be further developed as anticancer drugs.
Experimental Section
Chemistry
General Experimental Procedures—Reagents and solvents were obtained commercially
and used without further purification. Reactions were monitored by thin-layer chromatography,
using Merck plates with fluorescent indicator (TLC Silica gel 60 F254). Flash column
chromatography was performed on silica gel (Merck Slica gel 60, 40–63 µm) using a mixture
of CH2Cl2 and EtOH as eluant. Melting points were determined on a Yanaco MP-500D melting
point apparatus and were uncorrected. IR spectra were recorded on Shimadzu IRPrestige-21
spectrophotometers as KBr pellets. 1H NMR spectra were obtained on a Bruker NMR AV 400
spectrometer in DMSO. The following abbreviations are used: s, singlet; d, doublet; t, triplet;
m, multiplet; dd, double doublet; td, triple doublet; ddd, double double doublet. EI-MS spectra
were measured with an HP 5995 GC–MS instrument. ESI-MS spectra were measured with a
Bruker HCT ultra PTM Discovery system (Proteineer fc, UltiMate 3000). Elemental analyses
(C, H, and N) were performed on a Perkin-Elmer 2400 Series II CHNS/O analyzer, and the
results were within ±0.4% of the calculated values.
Preparation of arylcarbonyl chlorides (14–24)—Arylcarboxylic acids (3–13) were
suspended in dry toluene (150 mL) at 20 ± 2 °C. Oxalyl chloride (2.2 eq) was added dropwise.
The reaction mixtures were stirred for 30 min at 20 ± 2 °C, then DMF (2 drops) was added.
The mixtures were stirred for 6 h, and then evaporated to dryness. The residues were washed
with petroleum ether and used directly in the next step.
Preparation of carboxamides (25–35, 55)—Into solutions of 14–24 (5.1 mmol) in 200
mL of dry toluene were added triethylamine (4 mL) and 2-amino-4,5-methylenedioxy
acetophenone (2) (5 mmol). The mixtures were stirred at 20 ± 2 °C for 24 h, then evaporated.
The residues were washed with acetone and EtOH, and then recrystallized from acetone or
EtOH to form the pure carboxamides.
N-(6-Acetyl-1,3-benzodioxol-5-yl)-1-benzothiophene-3-carboxamide (25)—
Obtained as a pale yellow solid from 2-amino-4,5-methylenedioxyacetophenone (2) and benzo
[b]thiophene-3-carbonyl chloride (14). mp 213–214 °C; MS (ESI) 340 m/z [M+H]+. 1H NMR
(400 MHz, DMSO-d6, δ): 2.63 (3H, s), 6.18 (2H, s), 7.43–7.53 (2H, m), 7.66 (1H, s), 8.10 (1H,
dd, J = 1.2, 7.2 Hz), 8.30 (1H, s), 8.47 (1H, dd, J = 1.2, 7.2 Hz), 8.53 (1H, s), 12.75 (1H, s).
IR (KBr): 1638, 1668 (C=O) cm−1.
N-(6-Acetyl-1,3-benzodioxol-5-yl)-1-benzothiophene-2-carboxamide (26)—
Obtained as a grayish white solid from 2 and benzo[b]thiophene-2-carbonyl chloride (15). mp
233–235 °C; MS (ESI) 340 m/z [M+H]+. 1H NMR (400 MHz, DMSO-d6, δ): 2.69 (3H, s),
6.19 (2H, s), 7.46–7.57 (2H, m), 7.71 (1H, s), 8.09–8.13 (2H, m), 8.14 (1H, s), 8.25 (1H, s),
13.11 (1H, s). IR (KBr): 1640, 1655 (C=O) cm−1.
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a pale yellow solid from 2 and benzo[b]furan-3-carbonyl chloride (16). mp 144–145 °C; MS
(ESI) 324 m/z [M+H]+. 1H NMR (400 MHz, DMSO-d6, δ): 2.63 (3H, s), 6.19 (2H, s), 7.41–
7.50 (2H, m), 7.68 (1H, s), 7.75 (1H, dd, J = 1.6, 6.8 Hz), 8.15 (1H, dd, J = 2.0, 8.8 Hz), 8.27
(1H, s), 8.71 (1H, s), 12.63 (1H,s). IR (KBr): 1635, 1677 (C=O) cm−1.
N-(6-Acetyl-1,3-benzodioxol-5-yl)-1-benzofuran-2-carboxamide (28)—Obtained as
a grayish white solid from 2 and benzo[b]thiophene-2-carbonyl chloride (17). mp 184–185 °
C; MS (ESI) 324 m/z [M+H]+. 1H NMR (400 MHz, DMSO-d6, δ): 2.69 (3H, s), 6.20 (2H, s),
7.40 (1H, t, J = 7.6 Hz), 7.55 (1H, td, J = 1.2, 7.8 Hz), 7.72–7.78 (3H, m), 7.84 (1H, d, J = 8.0
Hz), 8.36 (1H, s) 13.21 (1H, s). IR (KBr): 1667, 1682 (C=O) cm−1.
N-(6-Acetyl-1,3-benzodioxol-5-yl)naphthalene-1-carboxamide (29)—Obtained as a
grayish white solid from 2 and naphthalene-1-carbonyl chloride (18). mp 143–144 °C; MS
(ESI) 334 m/z [M+H]+. 1H NMR (400 MHz, DMSO-d6, δ): 2.59 (3H, s), 6.20 (2H, s), 7.60–
7.68 (4H, m), 7.87 (1H, d, J = 7.2 Hz), 8.05–8.07 (1H, m), 8.15 (1H, d, J = 8.0 Hz), 8.33–8.38
(2H, m), 12.52 (1H, s). IR (KBr): 1647, 1672 (C=O) cm−1.
N-(6-Acetyl-1,3-benzodioxol-5-yl)naphthalene-2-carboxamide (30)—Obtained as a
pale yellow solid from 2 and naphthalene-2-carbonyl chloride (19). mp 172–173 °C; MS (ESI)
334 m/z [M+H]+. 1H NMR (400 MHz, DMSO-d6, δ): 2.68 (3H, s), 6.19 (2H, s), 7.64–7.72
(3H, m), 7.99–8.06 (2H, m), 8.15 (2H, d, J = 8.8 Hz), 8.42 (1H, s), 8.58 (1H, s), 13.09 (1H, s).
IR (KBr): 1636, 1670 (C=O) cm−1.
N-(6-Acetyl-1,3-benzodioxol-5-yl)quinoline-4-carboxamide (31)—Obtained as a
grayish white solid from 2 and quinoline-4-carbonyl chloride (20). mp 166–167 °C; MS (ESI)
335 m/z [M+H]+. 1H NMR (400 MHz, DMSO-d6, δ): 2.59 (3H, s), 6.21 (2H, s), 7.69 (1H, s),
7.72 (1H, ddd, J = 1.2, 7.2 Hz), 7.81 (1H, d, J = 4.4 Hz), 7.87 (1H, ddd, J = 1.2, 7.4 Hz), 8.15
(1H, d, J = 8.4 Hz), 8.24 (1H, s), 8.31 (1H, d, J = 8.4 Hz), 9.09 (1H, d, J = 4.2 Hz), 12.48 (1H,
s). IR (KBr): 1645, 1680 (C=O) cm−1.
N-(6-Acetyl-1,3-benzodioxol-5-yl)quinoline-3-carboxamide (32)—Obtained as a
pale yellow solid from 2 and quinoline-3-carbonyl chloride (21). mp 215–216 °C; MS (ESI)
335 m/z [M+H]+. 1H NMR (400 MHz, DMSO-d6, δ): 2.66 (3H, s), 6.21 (2H, s), 7.73 (1H, s),
7.76 (1H, ddd, J = 1.2, 7.4 Hz), 7.94 (1H, ddd, J = 1.6, 6.8 Hz), 8.15 (1H, d, J = 8.4 Hz), 8.23
(1H, d, J = 7.2 Hz), 8.34 (1H, s), 8.92 (1H, s), 9.38 (1H, s), 12.05 (1H, s). IR (KBr): 1639,
1670 (C=O) cm−1.
N-(6-Acetyl-1,3-benzodioxol-5-yl)quinoline-2-carboxamide (33)—Obtained as a
yellow solid from 2 and quinoline-2-carbonyl chloride (22). mp 210–211 °C; MS (ESI) 335
m/z [M+H]+. 1H NMR (400 MHz, DMSO-d6, δ): 2.69 (3H, s), 6.21 (2H, s), 7.73 (1H, s), 7.79
(1H, ddd, J = 1.2, 7.2 Hz), 7.95 (1H, ddd, J = 1.6, 7.6 Hz), 8.15 (1H, d, J = 7.2 Hz), 8.22 (1H,
d, J = 8.0 Hz), 8.28 (1H, d, J = 8.8 Hz), 8.55 (1H, s), 8.65–8.68 (1H, d, J = 8.8). IR (KBr):
1647, 1670 (C=O) cm−1.
N-(6-Acetyl-1,3-benzodioxol-5-yl)quinoline-5-carboxamide (34)—Obtained as a
yellow solid from 2 and quinoline-5-carbonyl chloride (23). mp 210–211 °C; MS (ESI) 335
m/z [M+H]+. 1H NMR (400 MHz, DMSO-d6, δ): 2.61 (3H, s), 6.21 (2H, s), 7.70 (1H, s), 7.82
(1H, dd, J = 4.4, 8.8 Hz), 8.03 (1H, t, J = 7.8 Hz), 8.11 (1H, d, J = 7.2 Hz), 8.30–8.35 (2H, m),
9.03 (1H, d, J = 8.4 Hz), 9.13 (1H, d, J = 4.4 Hz), 12.59 (1H, s). IR (KBr): 1636, 1672 (C=O)
cm−1.
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N-(6-Acetyl-1,3-benzodioxol-5-yl)anthracene-1-carboxamide (35)—Obtained as a
pale yellow solid from 2 and anthracene-1-carbonyl chloride (24). mp 206–207 °C; MS (ESI)
384 m/z [M+H]+. 1H NMR (400 MHz, DMSO-d6, δ): 2.59 (3H, s), 6.21 (2H, s), 7.55–7.61
(2H, m), 7.62–7.67 (1H, m), 7.70 (1H, s), 7.90 (1H, d, J = 6.8 Hz), 8.13–8.16 (2H, m), 8.32
(1H, d, J = 8.4 Hz), 8.46 (1H, s), 8.73 (1H, s), 9.03 (1H, s), 12.60 (1H, s). IR (KBr): 1643,
1674 (C=O) cm−1.
N-(6-Acetyl-1,3-benzodioxol-5-yl)-2-(naphthalen-1-yl)acetamide (55)—Obtained
as a white solid from 2 and 1-naphthylmethyl chloride (54). mp 89–90 °C; MS (ESI) 384 m/z
[M+H]+. 1H NMR (400 MHz, DMSO-d6, δ): 2.53 (3H, s), 4.21 (2H, s) 6.13 (2H, s), 7.50–7.61
(5H, m), 7.90 (1H, d, J = 8.0 Hz), 7.95 (1H, dd, J = 2.0, 7.2 Hz), 8.03 (1H, dd, J = 1.2, 8.0 Hz),
8.15 (1H, s), 11.89 (1H, s). IR (KBr): 1641, 1684 (C=O) cm−1.
Preparation of 2-aryl-6,7-methylenedioxyquinolin-4-ones (1, 37–44)
Method A: Into a suspension of 25, 27–34 (2.95 mmol) in t-butyl alcohol (100 mL) was added
potassium t-butoxide (1.66 g, 14.7 mmol). The mixture was refluxed under argon for 12 h,
cooled and poured into a 10% ammonium chloride solution (100 mL). The solid precipitate
was collected and washed with EtOH. The crude product was purified by flash chromatography
(silica gel, CH2Cl2:EtOH 16:1–10:1).
2-(3-Benzo[b]thienyl)-6,7-methylenedioxyquinolin-4-one (1)—35% yield from 25 as
a white solid. mp >330 °C; MS (ESI) 322 m/z [M+H]+. 1H NMR (DMSO-d6, δ): 6.15 (2H, s),
6.19 (1H, s), 7.11 (1H, s), 7.43 (1H, s), 7.47–7.54 (2H, m), 7.93 (1H, d, J = 7.6 Hz), 8.14 (1H,
d, J = 7.6 Hz), 8.24 (1H, s), 11.80 (1H, s). IR (KBr): 1616 (C=O) cm−1. Anal. Calcd for
C18H11NO3S: C, 67.00; H, 3.48; N, 4.25. Found: C, 67.28; H, 3.45; N, 4.36.
2-(3-Benzo[b]furyl)-6,7-methylenedioxyquinolin-4-one (37)—17% yield from 27 as
a pale yellow solid. mp >315 °C; MS (ESI) m/z 306 [M+H]+. 1H NMR (DMSO-d6, δ): 6.12
(2H, s), 6.49 (1H, s), 7.13 (1H, s), 7.36–7.45 (3H, m), 7.69 (1H, d, J = 8.0 Hz), 8.14 (1H, s),
8.52 (1H, s). IR (KBr): 1626 (C=O) cm−1. Anal. Calcd for C18H11NO4: C, 70.82; H, 3.63; N,
4.59. Found: C, 70.52; H, 3.95; N, 4.21.
2-(2-Benzo[b]furyl)-6,7-methylenedioxyquinolin-4-one (38)—28% yield from 28 as
a grayish white solid. mp >320 °C; MS (EI, 70 eV) m/z 305 [M]+. 1H NMR (DMSO-d6, δ):
6.19 (2H, s), 6.75 (1H, s), 7.30 (1H, s), 7.35 (1H, t, J = 7.6 Hz), 7.40 (1H, s), 7.45 (1H, t, J =
7.6 Hz), 7.71–7.79 (3H, m). IR (KBr): 1630 (C=O) cm−1. Anal. Calcd for C18H11NO4: C,
70.82; H, 3.63; N, 4.59. Found: C, 70.62; H, 3.84; N, 4.24.
2-(1-Naphthalenyl)-6,7-methylenedioxyquinolin-4-one (39)—52% yield from 29 as
a grayish white solid. mp >350 °C; MS (ESI) m/z 316 [M+H]+. 1H NMR (DMSO-d6, δ): 6.08
(1H, s), 6.15 (2H, s), 7.03 (1H, s), 7.46 (1H, s), 7.56–7.63 (2H, m), 7.63–7.70 (2H, m), 7.83
(1H, d, J = 7.6 Hz), 8.06 (1H, d, J = 7.6 Hz), 8.11 (1H, d, J = 7.6 Hz), 11.90 (1H, s). IR (KBr):
1653 (C=O) cm−1. Anal. Calcd for C20H13NO3: C, 76.18; H, 4.16; N, 4.44. Found: C, 75.60;
H, 3.94; N, 4.29.
2-(2-Naphthalenyl)-6,7-methylenedioxyquinolin-4-one (40)—48% yield from 30 as
a white solid. mp >330 °C; MS (ESI) m/z 316 [M+H]+. 1H NMR (DMSO-d6, δ): 6.16 (2H, s),
6.49 (1H, s), 7.25 (1H, s), 7.42 (1H, s), 7.59–7.64 (2H, m), 7.88–7.95 (1H, m), 8.00–8.03 (1H,
m), 8.06–8.12 (2H, m), 8.42 (1H, s). IR (KBr): 1616 (C=O) cm−1. Anal. Calcd for
C20H13NO3: C, 76.18; H, 4.16; N, 4.44. Found: C, 76.04; H, 4.28; N, 4.28.
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2-(4-Quinolinyl)-6,7-methylenedioxyquinolin-4-one (41)—54% yield from 31 as a
pale yellow solid. mp >320 °C; MS (ESI) m/z 317 [M+H]+. 1H NMR (DMSO-d6, δ): 6.12–
6.29 (3H, m), 7.06 (1H, s), 7.47 (1H, s), 7.65–7.70 (2H, m), 7.86 (1H, t, J = 7.6 Hz), 7.93 (1H,
d, J = 8.4 Hz), 8.15 (1H, d, J = 8.0 Hz), 9.03 (1H, s). IR (KBr): 1618 (C=O) cm−1. Anal. Calcd
for C19H12N2O3: C, 72.15; H, 3.82; N, 8.86. Found: C, 72.35; H, 4.03; N, 8.60.
2-(3-Quinolinyl)-6,7-methylenedioxyquinolin-4-one (42)—65% yield from 32 as a
grayish white solid, mp >320 °C; MS (ESI) m/z 317 [M+H]+. 1H NMR (DMSO-d6, δ): 6.19
(2H, s), 6.62 (1H, s), 7.23 (1H, s), 7.44 (1H, s), 7.73 (1H, t, J = 7.6 Hz), 7.87 (1H, t, J = 7.6
Hz), 8.11–8.17 (2H, m), 8.88 (1H, s), 9.38 (1H, s). IR (KBr): 1618 (C=O) cm−1. Anal. Calcd
for C19H12N2O3: C, 72.15; H, 3.82; N, 8.86. Found: C, 71.86; H, 3.76; N, 8.63.
2-(2-Quinolinyl)-6,7-methylenedioxyquinolin-4-one (43)—48% yield from 33 as a
pale yellow solid. mp 345–347 °C; MS (EI, 70 eV) m/z 316 [M]+. 1H NMR (DMSO-d6, δ):
6.18 (2H, s), 6.98 (1H, s), 7.43 (1H, s), 7.63 (1H, s), 7.73 (1H, t, J = 7.6 Hz), 7.91 (1H, t, J =
7.6 Hz), 8.11 (1H, d, J = 8.0 Hz), 8.27 (1H, d, J = 8.4 Hz), 8.32 (1H, d, J = 8.8 Hz), 8.60 (1H,
d, J = 8.8 Hz), 11.85 (1H, s). IR (KBr): 1611 (C=O) cm−1. Anal. Calcd for C19H12N2O3: C,
72.15; H, 3.82; N, 8.86. Found: C, 71.76; H, 3.88; N, 8.46.
2-(5-Quinolinyl)-6,7-methylenedioxyquinolin-4-one (44)—47% yield from 34 as a
pale yellow solid. mp >330 °C; MS (ESI) m/z 317 [M+H]+. 1H NMR (DMSO-d6, δ): 6.03–
6.19 (3H, m), 7.03 (1H, s), 7.47 (1H, s), 7.60 (1H, dd, J = 4.0, 8.4 Hz), 7.81 (1H, d, J = 6.8
Hz), 7.91 (1H, t, J = 7.8 Hz), 8.20 (1H, d, J = 8.4 Hz), 8.30 (1H, d, J = 6.4 Hz), 8.99 (1H, s),
11.91 (1H, s). IR (KBr): 1614 (C=O) cm−1. Anal. Calcd for C19H12N2O3: C, 72.15; H, 3.82;
N, 8.86. Found: C, 72.08; H, 3.94; N, 8.66.
Preparation of 2-aryl-6,7-methylenedioxyquinolin-4-ones (1, 36, 39, 45) and 4-
methyl-6,7-methylenedioxy-3-(1-naphthyl)quinolin-2-one (56)
Method B: Following the same procedure described in method A, except for the use of 1,4-
dioxane as solvent in place of t-butylalcohol, and the use of NaOH in place of potassium t-
butoxide. Compounds 1 and 39 were confirmed by comparison of mp and TLC with those of
a sample obtained from method A.
2-(3-Benzo[b]thienyl)-6,7-methylenedioxyquinolin-4-one (1)—40% yield from 25 as
a pale yellow solid.
2-(2-Benzo[b]thienyl)-6,7-methylenedioxyquinolin-4-one (36)—74% yield from 26
as a white solid. mp >350 °C; MS (ESI) m/z 322 [M+H]+. 1H NMR (DMSO-d6, δ): 6.20 (2H,
s), 7.21 (1H, s), 7.39–7.45 (3H, m), 7.96–8.16 (3H, m), 11.55 (1H, s). IR (KBr): 1616 (C=O)
cm−1. Anal. Calcd for C18H11NO3S: C, 67.00; H, 3.48; N, 4.25. Found: C, 67.21; H, 3.47; N,
4.33.
2-(1-Naphthalenyl)-6,7-methylenedioxyquinolin-4-one (39)—58% yield from 29 as
a grayish white solid.
2-(1-Anthracenyl)-6,7-methylenedioxyquinolin-4-one (45)—48% yield from 35 as a
yellow solid. mp >320 °C; MS (ESI) m/z 366 [M+H]+. 1H NMR (DMSO-d6, δ): 6.15 (3H, s),
7.03 (1H, s), 7.43–7.70 (5H, m), 8.08 (2H, t, J = 7.6 Hz), 8.25 (1H, d, J = 8.4 Hz), 8.47 (1H,
s), 8.70 (1H, s), 11.98 (1H, s). IR (KBr): 1632 (C=O) cm−1. Anal. Calcd for C24H15NO3: C,
78.89; H, 4.14; N, 3.83. Found: C, 78.24; H, 4.40; N, 3.37.
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4-Methyl-6,7-methylenedioxy-3-(1-naphthyl)quinolin-2-one (56)—61% yield from
55 as a white solid. mp >260 °C; MS (EI, 70 eV) m/z 329 [M]+. 1H NMR (DMSO-d6, δ): 2.02
(3H, s), 6.13 (2H, s), 6.91 (1H, s), 7.29–7.32 (2H, m), 7.39–7.47 (2H, m), 7.52 (1H, ddd, J =
1.6, 6.4 Hz), 7.58 (1H, t, J = 8.0 Hz), 7.93–8.01 (2H, m), 11.84 (1H, s). IR (KBr): 1632 (C=O)
cm−1. Anal. Calcd for C21H15NO3: C, 76.58; H, 4.59; N, 4.25. Found: C, 75.88; H, 5.07; N,
4.06.
Deacetylation of compounds 25, 26, 28–32 and 34—Into a suspension of compound
(2.95 mol) in dry toluene (150 mL) was added potassium t-butoxide (1.66 g, 14.75 mol). The
mixture was heated under argon at 90 °C for 72 h, and then concentrated and neutralized with
20% HOAc The resulting solid precipitate was collected and purified by flash chromatography
(silica gel, CH2Cl2-EtOH) to afford 46–53.
N-(1,3-Benzodioxol-5-yl)-1-benzothiophene-3-carboxamide (46)—28% yield from
25 as a white solid. mp 188−189 °C; MS (EI, 70 eV) m/z 297 [M]+. 1H NMR (DMSO-d6, δ):
6.01 (2H, s), 6.90 (1H, d, J = 8.4 Hz), 7.17 (1H, dd, J = 2.0, 8.4 Hz), 7.40−7.51 (3H, m), 8.06
(1H, dd, J = 1.2, 7.2 Hz), 8.37 (1H, dd, J = 0.8, 8.0 Hz), 8.46 (1H, s), 10.29 (1H, s). IR (KBr):
1647 (C=O) cm−1. Anal. Calcd for C16H11NO3S: C, 64.63; H, 3.73; N, 4.71. Found: C, 64.32;
H, 3.94; N, 4.50.
N-(1,3-Benzodioxol-5-yl)-1-benzothiophene-2-carboxamide (47)—36% yield from
26 as a grayish white solid. mp 171−173 °C; MS (EI, 70 eV) m/z 297 [M]+. 1H NMR (DMSO-
d6, δ): 6.01 (2H, s), 6.91 (1H, d, J = 8.4 Hz), 7.15 (1H, dd, J = 2.0, 8.4 Hz), 7.38 (1H, d, J =
2.4 Hz), 7.41−7.54 (2H, m), 7.96–8.05 (2H, m), 8.28 (1H, s), 10.41 (1H, s). IR (KBr): 1634
(C=O) cm−1. Anal. Calcd for C16H11NO3S: C, 64.63; H, 3.73; N, 4.71. Found: C, 64.28; H,
3.98; N, 4.46.
N-(1,3-Benzodioxol-5-yl)-1-benzofuran-2-carboxamide (48)—28% yield from 28 as
a yellow solid. mp 156-158 °C; MS (EI, 70 eV) m/z 281 [M]+. 1H NMR (DMSO-d6, δ): 6.03
(2H, s), 6.93 (1H, d, J = 8.4 Hz), 7.27 (1H, dd, J = 2.0, 8.4 Hz), 7.37 (1H, t, J = 7.6 Hz), 7.47
(1H, d, J = 2.0 Hz), 7.51 (1H, ddd, J = 2.0, 8.4 Hz), 7.71–7.75 (2H, m), 7.82 (1H, d, J = 8.0
Hz), 10.49 (1H, s). IR (KBr): 1668 (C=O) cm−1. Anal. Calcd for C16H11NO4: C, 68.32; H,
3.94; N, 4.98. Found: C, 68.22; H, 4.14; N, 4.22.
N-(1,3-Benzodioxol-5-yl)naphthalene-1-carboxamide (49)—32% yield from 29 as a
white solid. mp 204–206 °C; MS (EI, 70 eV) m/z 291 [M]+. 1H NMR (DMSO-d6, δ): 6.02
(2H, s), 6.91 (1H, d, J = 8.4 Hz), 7.22 (1H, dd, J = 2.0, 8.4 Hz), 7.51 (1H, d, J = 2.0 Hz), 7.56–
7.63 (3H, m), 7.72 (1H, d, J = 6.4 Hz), 7.99–8.03 (1H, m), 8.06 (1H, d, J = 8.4 Hz), 8.16–8.20
(1H, m), 10.46 (1H, s). IR (KBr): 1643 (C=O) cm−1. Anal. Calcd for C18H13NO3: C, 74.22;
H, 4.50; N, 4.81. Found: C, 73.83; H, 4.82; N, 4.26.
N-(1,3-Benzodioxol-5-yl)naphthalene-2-carboxamide (50)—21% yield from 30 as a
pale yellow solid. mp 184–185 °C; MS (EI, 70 eV) m/z 291 [M]+. 1H NMR (DMSO-d6, δ):
6.02 (2H, s), 6.94 (1H, d, J = 8.4 Hz), 7.24 (1H, dd, J = 2.0, 8.4 Hz), 7.50 (1H, d, J = 2.0 Hz),
7.60–7.68 (2H, m), 7.98–8.15 (4H, m), 8.56 (1H, s), 10.38 (1H, s). IR (KBr): 1636 (C=O)
cm−1. Anal. Calcd for C18H13NO3: C, 74.22; H, 4.50; N, 4.81. Found: C, 74.19; H, 4.62; N,
4.56.
N-(1,3-Benzodioxol-5-yl)quinoline-4-carboxamide (51)—31% yield from 31 as a
white solid. mp 167–168 °C; MS (EI, 70 eV) m/z 292 [M]+. 1H NMR (DMSO-d6, δ): 6.02
(2H, s), 6.93 (1H, d, J = 8.4 Hz), 7.16 (1H, dd, J = 1.6, 8.4 Hz), 7.43 (1H, d, J = 2.0 Hz), 7.66–
7.72 (2H, m), 7.84 (1H, t, J = 8.0 Hz), 8.11 (2H, d, J = 8.8 Hz), 9.01 (1H, s), 10.65 (1H, s). IR
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(KBr): 1636 (C=O) cm−1. Anal. Calcd for C17H12N2O3: C, 69.86; H, 4.14; N, 9.58. Found: C,
69.65; H, 4.32; N, 9.34.
N-(1,3-Benzodioxol-5-yl)quinoline-3-carboxamide (52)—23% yield from 32 as a
yellow solid. mp 254–256 °C; MS (EI, 70 eV) m/z 292 [M]+. 1H NMR (DMSO-d6, δ): 6.05
(2H, s), 6.95 (1H, d, J = 8.4 Hz), 7.23 (1H, dd, J = 2.0, 8.4 Hz), 7.49 (1H, d, J = 2.0 Hz), 7.74
(1H, ddd, J = 1.2, 8.0 Hz), 7.90 (1H, ddd, J = 1.6, 8.4 Hz), 8.10–8.18 (2H, m), 8.92 (1H, s),
9.33 (1H, s), 10.56 (1H, s). IR (KBr): 1659 (C=O) cm−1. Anal. Calcd for C17H12N2O3: C,
69.86; H, 4.14; N, 9.58. Found: C, 69.73; H, 4.35; N, 9.42.
N-(1,3-Benzodioxol-5-yl)quinoline-5-carboxamide (53)—20% yield from 34 as a
white solid. mp 202–203 °C; MS (EI, 70 eV) m/z 292 [M]+. 1H NMR (DMSO-d6, δ): 6.02
(2H, s), 6.95 (1H, d, J = 8.4 Hz), 7.21 (1H, dd, J = 2.0, 8.0 Hz), 7.50 (1H, d, J = 2.0 Hz), 7.63
(1H, dd, J = 4.0, 8.4 Hz), 7.83–7.90 (2H, m), 8.16–8.20 (1H, m), 8.63 (1H, d, J = 8.0 Hz), 8.98
(1H, dd, J = 1.6, 4.0 Hz), 10.58 (1H, s). IR (KBr): 1643 (C=O) cm−1. Anal. Calcd for
C17H12N2O3: C, 69.86; H, 4.14; N, 9.58. Found: C, 69.68; H, 4.33; N, 9.52.
Biological Evaluations
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays 25,26
—HL-60, HCT-116 and Hep 3B cells were treated with tested compounds for the indicated
periods. After treatment, cells were washed once with PBS and incubated with MTT (Sigma,
St. Louis, MO, USA) for 2 h. The formazan precipitate was dissolved in 150 µL of DMSO,
and the absorbance was measured with an ELISA reader at 570 nm.
SRB assays 27—A549, KB, KB-VIN and DU145 cells were treated with tested compounds
for the indicated periods. After additional incubation with DMSO or compounds, cells were
fixed with 10% TCA, and SRB at 0.4% (w/v) in 1% acetic acid was added to stain cells.
Unbound SRB was washed out with 1% acetic acid, and SRB bound to the cells was solubilized
with 10 mM Trizma base. Absorbance was read at 515 nm.
Tubulin assays—Tubulin assembly was measured by turbidimetry as described in detail
previously.28 Assay mixtures contained 1.0 mg/mL (10 µM) tubulin and varying drug
concentrations and were preincubated 15 min at 30 °C in the absence of GTP. The samples
were placed on ice, and 0.4 mM GTP was added. Reaction mixtures were transferred to cuvettes
held at 0 °C, and turbidity development was followed for 20 min at 30 °C after a rapid
temperature jump. Drug concentrations that inhibited increase in turbidity by 50% relative to
a control sample were determined.
Inhibition of the binding of [3H]colchicine to tubulin was measured as described in detail
previously.29 Incubation of 1.0 µM tubulin with 5.0 µM [3H]colchicine and either 1.0 or 5.0
µM inhibitor was for 10 min at 37 °C. At this time point, approximately 40–60% of maximum
colchicine binding occurs.
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Three series of structural skeletons of azo-flavonoids: 2-arylquinolone-4-ones, 2-
arylnaphthyridin-4-ones, and 2-arylquinazolin-4-ones.
Chang et al. Page 13














Proposed models and newly designed compounds. Conventional Comparative Molecular Field
Analysis (CoMFA) and g2 GRS CoMFA are two computational programs performed to identify
the essential structure requirements for increasing affinity at the colchicine site of tubulin.
Based on the results of the QSAR study, we proposed two concept models. As the proof of
concept, analog A was synthesized and tested against cancer cell lines and for binding to
tubulin.
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Structures of compound B and CHM-1.
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Metabolic pathway of CHM-1-P-Na.
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Dose response curves of 37 against different leukemia cell lines.
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Reagents and conditions: (a) toluene/DMF, 22–25 °C; (b) toluene/triethylamine, 22–25 °C; (c)
t-BuOK/ t-BuOH or NaOH/1,4-dioxane, reflux; (d) t-BuOK/toluene, 90 °C, 72 h.
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Reagents and conditions: (a) toluene/triethylamine, 22–25 °C; (b) NaOH/1,4-dioxane, reflux.
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Table 2
Anti-tubulin Data for CA-4, 1 and 37-45.
Compound Inhibition of Tubulin Assembly
a
IC50 (µM) ± SD
Inhibition of Colchicine Bindingb
% inhibition at tested concentration
1 µM 5 µM
CA-4 1.2 ± 0.2 91 99
1 0.76 ± 0.06 25 61
37 0.58 ± 0.02 39 51
38 > 4 - -
39 0.64 ± 0.07 33 67
40 > 40 - -
41 > 40 - -
42 > 4 - -
43 > 40 - -
44 27 ± 3 - -
45 > 40 - -
a
Assembly assay contained 10 µM tubulin.
b
Colchicine binding assay contained 1 µM tubulin and 5 µM [3H]colchicine.
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